15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering HealthStream Inc, 0 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $27.00 to $27.00, so the covering firms are broadly aligned. The average target of $27.00 sits 6% below the current $28.86. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.19 next quarter toward $0.86 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Hold
Strong Buy00%
Buy00%
Hold1100%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to HealthStream Inc.
As of Jul, 0 of 1 firms rate HSTM a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
HSTM EPS & revenue forecast
EPS · NEXT QUARTER
$0.19
Range $0.17 – $0.21 · 2 analysts · -5% YoY
Next period, 2 analysts expect HealthStream Inc to earn $0.19 a share (range $0.17 – $0.21), versus $0.20 a year earlier. Full-year consensus is $0.79, growing to $0.86 the year after.
REVENUE · NEXT QUARTER
$81.9M
Range $81.7M – $82.3M · 2 analysts · +7% YoY
Revenue is expected to reach $81.9M (range $81.7M – $82.3M), +7.1% year-over-year. Full-year consensus is $327.3M, rising to $343.3M next year.
Top analysts covering HealthStream Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HSTM.
#1
Constantine Davides
JMP Securities · Rank #225
Hold
No targeton HSTM
Overall win rate
34%
+ Follow
#2
Richard Close
Canaccord Genuity
Hold
$27.00-6.4% to target
Coverage
—
+ Follow
HSTM stock forecast FAQ
What is HSTM's average 12-month price target?+
The 1 analysts with a live target average $27.00 for HealthStream Inc over the next 12 months, ranging from a $27.00 high to a $27.00 low.
Is HSTM stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 1 analyst ratings, 0 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover HSTM?+
1 analysts have an active rating on HealthStream Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering HSTM?+
Among analysts who currently cover HSTM, Constantine Davides of JMP Securities has the strongest overall Quantellect track record (Rank #225). Their current call is Hold.
What is HealthStream Inc's projected EPS for next quarter?+
The consensus estimate is $0.19 per share (range $0.17 – $0.21) across 2 analysts. Full-year EPS is projected at $0.79, rising to $0.86 the following year.
How much revenue is HealthStream Inc expected to report next quarter?+
Consensus revenue is $81.9M (range $81.7M – $82.3M). Full-year revenue is projected at $327.3M, growing to $343.3M next year.
Have analysts been upgrading or downgrading HSTM lately?+
As of Jul, 0 of 1 firms rate HSTM a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HSTM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
